Contemporary Total Cost of Care Among Medicare Patients with Primary and Recurrent Clostridioides Difficile Infection
Amin A1, Guo A2, Teigland C3, Mohammadi I3, Schablik J4, Reveles K5
1University of California, Irvine, CA, USA, 2Ferring Pharmaceuticals, Inc., Parsippany, NJ, USA, 3Avalere Health, an Inovalon Company, Washington, DC, USA, 4Avalere Health, an Inovalon Company, Roxboro, NC, USA, 5The University of Texas at Austin, San Antonio, TX, USA
METHODS: Using 100% Medicare Parts A, B, and D claims between 2009-2017, we identified patients aged ≥65, continuously enrolled for 12-months with no evidence of CDI prior to index CDI and up to 12-months post-index. Total costs of care were calculated as per-patient-per-month (PPPM) overall and separately for patients with CDI-linked death, defined as patients whose most proximal healthcare visit on or near date of death had CDI in primary/secondary diagnosis field.
RESULTS: Of 497,489 CDI patients included, 42.8% overall died within 12 months after index CDI. Mortality rates increased with recurrences for deaths that were CDI-linked (pCDI 2.7%, 1rCDI 16.4%, 2rCDI 30.9%, 3+rCDI 50%). CDI was a primary contributing diagnosis to 50% of the deaths in patients with 3+ recurrences. Mean (SD) PPPM costs for pCDI patients who died was $29,150 ($33,256) versus $6,348 ($7,117) for those who survived, and PPPM costs for patients with CDI-linked death was $24,883 ($16,435). Mean PPPM costs in patients with any recurrence was $35,767 for rCDI patients who died versus $7,959 who survived, and $28,443 for CDI-linked death. Costs were driven largely by inpatient stays (41%-75% of total cost); 99.9% of patients with recurrence and CDI-linked death were hospitalized, with 52.7% requiring intensive care, and 77.9% readmitted at least once.CONCLUSION: Despite currently available treatments, CDI patients had substantial mortality and costs. Costly hospitalizations and readmissions requiring intensive patient care resulted in 3.5x higher monthly costs in rCDI patients who died than patients who survived. New treatments reducing CDI recurrences are needed to improve economic/clinical burden and mortality.
Conference/Value in Health Info
Value in Health, Volume 25, Issue 6, S1 (June 2022)
Clinical Outcomes, Economic Evaluation, Real World Data & Information Systems, Study Approaches
Clinical Outcomes Assessment, Health & Insurance Records Systems
No Additional Disease & Conditions/Specialized Treatment Areas